{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 64,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a hub-and-spoke diagram to centralize the problem of neurotoxicity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/7",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.65,
        "y": 0.45
      },
      "kind": "callout",
      "text": "Memorial Sloan Kettering Cancer Center quote: Chimeric antigen receptor (CAR) T-cell therapy is highly effective ... but is hindered by neurotoxicity.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a89e4b4e-4c13-42ed-882a-ec32a2ba66f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.85,
        "x": 0.08,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "CAR-T Neurotoxicity central hub with four spokes: Parkinson's Like Symptoms, Long Hospital Stay, Limited Hospital Access, Patient Deaths",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c22a39a3-0a54-4452-ab95-be07ac6eb889",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "Neurotoxicity Restricts CAR-T Adoption",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "550ecbf4-65fa-42ed-9e41-4917806adda1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "8dfe3d59-9014-4302-b8eb-67d4092759c4",
      "evidence": "Neurotoxicity Restricts CAR-T Adoption",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "ffec05ed-9b70-4300-bfe1-1923a39af951",
      "evidence": "Central node connected to peripheral nodes",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "c962cea8-102a-4bc7-8d0f-aa1442fcfcf5",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Slides 7-8 highlight the problem of neurotoxicity in CAR-T therapies and its impact on AL Amyloidosis and multiple myeloma",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 8,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "121a95bf-b39f-4f50-b7d1-f7d3a325321e",
      "evidence": "Slides 7-8 highlight the limitations of current CAR-T therapies",
      "position": 0,
      "objective": "What is the cost of inaction for current CAR-T therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}